Hospital
Danville Regional Medical Center LLC
Danville Regional Medical Center LLC was paid $21.09M by Medicaid between Jan 2018 and Dec 2022, across 252 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoDANVILLE REGIONAL MEDICAL CENTER LLC
MARTINSVILLE, VA 24112
MARTINSVILLE, VA 24112
33aNPI1386720183assigned 10/27/2006
33bProvider typeRural Acute Care Hospital
28Total paid$21.09M
24GClaims598,580
24DCodes billed252
24AFirst – last monthJan 2018 – Dec 2022
Compared with peers
Next to other Rural Acute Care Hospital providers in Virginia
Rank by total paid#3 of 6
Median peer was paid$20.60M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,578 | $2.27M | |
| 2019 | 144,275 | $5.09M | |
| 2020 | 116,684 | $4.29M | |
| 2021 | 142,030 | $5.07M | |
| 2022 | 116,013 | $4.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 22,738 | 20,039 | $3.68M |
| 96361 | Intravenous infusion, hydration; each additional hour | 17% | 13,435 | 10,811 | $3.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 19,370 | 17,652 | $2.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 10,133 | 9,132 | $1.69M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 3,412 | 3,196 | $797K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 4,460 | 4,116 | $785K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 5,480 | 5,132 | $782K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 5,362 | 4,276 | $484K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,987 | 1,850 | $449K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.9% | 2,583 | 2,061 | $393K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 2,972 | 2,768 | $375K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 576 | 552 | $330K |
240 more codes
| 96367 | 1.5% | 1,530 | $318K | |
| G0378 | Hospital observation service, per hour | 1.5% | 2,462 | $309K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 6,315 | $291K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 3,629 | $266K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 924 | $257K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,021 | $209K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,318 | $200K |
| 80053 | Comprehensive metabolic panel | <1% | 31,851 | $194K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,973 | $181K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,387 | $154K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,896 | $149K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,923 | $133K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,114 | $109K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,785 | $106K |
| 10060 | <1% | 602 | $94K | |
| 93970 | <1% | 700 | $87K | |
| 83880 | <1% | 6,371 | $75K | |
| 76830 | Ultrasound, transvaginal | <1% | 598 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,116 | $68K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,111 | $67K |
| 87040 | <1% | 6,768 | $63K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 115 | $56K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 69 | $52K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,549 | $52K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,534 | $48K |
| 84145 | <1% | 3,612 | $46K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,045 | $42K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,341 | $41K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,226 | $40K |
| 76642 | <1% | 334 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,046 | $37K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 278 | $37K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 59 | $36K |
| 72100 | <1% | 1,927 | $35K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,670 | $34K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,460 | $34K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,539 | $34K |
| 29125 | <1% | 282 | $33K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,376 | $31K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,892 | $26K |
| 74018 | <1% | 2,127 | $26K | |
| 12001 | <1% | 88 | $24K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 415 | $23K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 767 | $22K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,219 | $21K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 272 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,427 | $19K |
| 85379 | <1% | 2,483 | $19K | |
| 93017 | <1% | 130 | $18K | |
| 84484 | <1% | 11,392 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 17,327 | $16K |
| 76770 | <1% | 124 | $15K | |
| 76801 | <1% | 196 | $14K | |
| 85027 | <1% | 3,017 | $14K | |
| 97161 | <1% | 1,020 | $13K | |
| 73630 | <1% | 1,133 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,930 | $12K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $12K |
| 73610 | <1% | 1,249 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,176 | $11K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 418 | $10K |
| 76536 | <1% | 70 | $10K | |
| 97016 | <1% | 240 | $9K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,030 | $9K |
| 73030 | <1% | 1,083 | $9K | |
| 59025 | Fetal non-stress test | <1% | 62 | $9K |
| 83605 | <1% | 6,101 | $8K | |
| 43235 | <1% | 13 | $8K | |
| 73130 | <1% | 1,099 | $8K | |
| 87081 | <1% | 5,555 | $8K | |
| 82607 | <1% | 804 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 40 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,347 | $8K |
| 82728 | <1% | 1,368 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 564 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,589 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,006 | $7K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 95 | $7K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 238 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,981 | $7K |
| 81001 | <1% | 21,901 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $7K |
| 73564 | <1% | 347 | $6K | |
| 73502 | <1% | 625 | $6K | |
| 83735 | <1% | 6,333 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,080 | $6K |
| 82553 | <1% | 1,970 | $6K | |
| 80061 | Lipid panel | <1% | 1,475 | $5K |
| 82962 | <1% | 6,853 | $5K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 353 | $4K |
| 81025 | <1% | 3,805 | $4K | |
| 94010 | <1% | 87 | $4K | |
| 83550 | <1% | 1,415 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 176 | $4K |
| 84702 | <1% | 1,535 | $4K | |
| 87077 | <1% | 2,868 | $4K | |
| 96368 | <1% | 767 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,984 | $4K |
| 83540 | <1% | 1,456 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,400 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 223 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,053 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,827 | $3K |
| 97116 | <1% | 181 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 73 | $3K |
| 73110 | <1% | 402 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,201 | $3K |
| 90715 | <1% | 200 | $3K | |
| 36600 | <1% | 3,401 | $3K | |
| 71250 | <1% | 43 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $3K |
| 85610 | <1% | 10,291 | $3K | |
| 72050 | <1% | 135 | $3K | |
| 84439 | <1% | 445 | $2K | |
| 0001A | <1% | 156 | $2K | |
| 94726 | <1% | 86 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,832 | $2K |
| 0012A | <1% | 76 | $2K | |
| 73562 | <1% | 408 | $2K | |
| 87070 | <1% | 528 | $2K | |
| 94150 | <1% | 87 | $2K | |
| 94729 | <1% | 86 | $2K | |
| 87210 | <1% | 1,393 | $2K | |
| 86850 | <1% | 1,084 | $2K | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 15 | $2K |
| 70491 | <1% | 12 | $2K | |
| 85652 | <1% | 1,261 | $2K | |
| 29515 | <1% | 13 | $2K | |
| 86140 | <1% | 498 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,409 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,429 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 69 | $2K |
| 82805 | <1% | 3,593 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13 | $2K |
| 87186 | <1% | 2,914 | $1K | |
| 90714 | <1% | 103 | $1K | |
| 86900 | <1% | 1,515 | $1K | |
| 70486 | <1% | 28 | $1K | |
| 82550 | <1% | 6,379 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 42 | $1K |
| 71271 | <1% | 13 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 467 | $1K |
| 0011A | <1% | 79 | $1K | |
| 72070 | <1% | 53 | $1K | |
| 83615 | <1% | 664 | $1K | |
| 82746 | <1% | 253 | $983.63 | |
| 72040 | <1% | 26 | $943.75 | |
| 74019 | <1% | 41 | $941.09 | |
| 76870 | <1% | 15 | $887.93 | |
| 86618 | <1% | 82 | $859.79 | |
| 86901 | <1% | 1,514 | $831.93 | |
| 73590 | <1% | 116 | $806.88 | |
| 93971 | <1% | 13 | $798.82 | |
| 82565 | <1% | 177 | $735.86 | |
| 0002A | <1% | 25 | $734.68 | |
| 83690 | <1% | 8,456 | $728.23 | |
| 84703 | <1% | 4,796 | $713.16 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,416 | $674.57 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 307 | $670.30 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $654.26 |
| 85730 | <1% | 8,906 | $632.64 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,463 | $618.04 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,733 | $604.88 |
| 87428 | <1% | 956 | $601.70 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,388 | $591.34 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 912 | $576.08 |
| 73560 | <1% | 64 | $526.59 | |
| 73080 | <1% | 95 | $526.13 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,481 | $515.61 |
| 86300 | <1% | 29 | $498.69 | |
| 84100 | <1% | 760 | $482.94 | |
| 82784 | <1% | 123 | $480.07 | |
| 51702 | <1% | 31 | $471.27 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,842 | $456.04 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,419 | $423.01 |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $417.64 |
| 86003 | <1% | 65 | $402.80 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,501 | $350.33 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,667 | $335.67 |
| 87807 | <1% | 1,353 | $331.74 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,673 | $323.21 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 85 | $284.61 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,006 | $268.79 |
| 86757 | <1% | 38 | $239.84 | |
| 80164 | <1% | 27 | $236.10 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $234.13 |
| 82570 | <1% | 48 | $205.80 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,256 | $194.91 |
| 88342 | <1% | 109 | $192.54 | |
| 73090 | <1% | 53 | $190.37 | |
| 88304 | <1% | 347 | $187.19 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,151 | $186.13 |
| 82274 | <1% | 481 | $173.16 | |
| 80178 | <1% | 14 | $150.84 | |
| 86803 | <1% | 14 | $150.47 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,720 | $148.89 |
| 73552 | <1% | 32 | $144.11 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,359 | $135.91 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 547 | $131.53 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 118 | $125.71 |
| 87205 | <1% | 321 | $119.20 | |
| 96376 | <1% | 2,450 | $118.74 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,139 | $115.43 |
| 83883 | <1% | 14 | $112.15 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,141 | $110.09 |
| 84153 | <1% | 14 | $107.79 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,214 | $91.95 |
| 82043 | <1% | 32 | $76.94 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 166 | $74.07 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 596 | $58.92 |
| 73140 | <1% | 12 | $54.66 | |
| 84480 | <1% | 18 | $54.55 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 14 | $52.07 |
| 82785 | <1% | 12 | $46.66 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 419 | $45.50 |
| 99152 | <1% | 69 | $40.72 | |
| 84165 | <1% | 17 | $40.14 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 543 | $37.07 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 405 | $32.76 |
| 87340 | <1% | 13 | $32.18 | |
| 87147 | <1% | 60 | $29.18 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 299 | $24.81 |
| 82140 | <1% | 44 | $21.08 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 32 | $13.14 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 100 | $12.22 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 52 | $7.90 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 94 | $6.35 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 41 | $4.16 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 45 | $3.54 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 26 | $0.92 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 28 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 39 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 13 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 52 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 14 | $0.00 |
| 82010 | 0% | 43 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 30 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 13 | $0.00 |
| 86308 | 0% | 13 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 62 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.